Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. ...
예상 EPS $-0.26 · 매출 $21.93M · 3 명의 애널리스트
예상 EPS $-0.21 · 매출 $25.28M · 3 명의 애널리스트
예상 EPS $-1.02 · 매출 $90.54M · 4 명의 애널리스트
예상 EPS $-0.25 · 매출 $23.12M · 1 명의 애널리스트
| 지표 | 최신 | 전년 대비YoY는 Year-over-Year(전년 대비)를 의미합니다. 최근 연도 값을 이전 연도 값과 비교하여 장기 추세의 강도를 보여줍니다. | 전분기 대비QoQ는 Quarter-over-Quarter(전분기 대비)를 의미합니다. 최근 분기를 직전 분기와 비교하여 단기 모멘텀 변화를 보여줍니다. |
|---|---|---|---|
| 매출고객에게 물건을 판매하여 청구서가 지급되기 전까지 들어온 총 금액입니다. 고객의 모든 카드 결제의 총합이라고 보시면 됩니다. (YoY는 올해를 작년 성과와 비교하며, QoQ는 최근 3개월을 이전 3개월과 비교합니다). | $90.5M | +8.0% | +10.5% |
| 순이익절대적인 최종 이익입니다. 회사가 모든 공급업체, 직원, 은행, 세무 당국에 비용을 지불하고 남은 실제 금액입니다. | $-54.0M | +4.2% | +26.2% |
| 매출총이익률기본적인 마진입니다. 100달러짜리 운동화를 판매한다면, 이 비율은 원료와 끈 비용을 지불한 직후의 이익이 가격의 얼마인지를 나타내며, 매장 임대료나 TV 광고 같은 비용은 제외됩니다. | +74.2% | +0.3% | +0.0% |
| 영업이익률본업의 효율성 점수입니다. 고객이 지불하는 1달러 중에서 제품을 만들고 모든 일상적인 회사 운영비(급여, 마케팅, 임대료 등)를 지불한 후 회사가 보유하는 금액을 나타냅니다. | -59.3% | +13.9% | +36.8% |
| 순이익률최종 이익 비율입니다. 모든 비용, 세금, 이자를 차감한 후, 매출 1달러 중 회사가 실제로 보유하는 정확한 액수입니다. | -59.7% | +11.3% | +33.2% |
| 잉여현금흐름기업 현금흐름의 핵심입니다. 일상적인 운영비를 지불하고 생존에 필요한 큰 설비(공장, 서버 등)에 투자한 후 남은 사용 가능한 실제 현금입니다. 배당금이나 자사주 매각에 사용될 수 있는 '자유' 현금입니다. | $-32.9M | +0.3% | +48.4% |
| FCF 마진궁극의 현금 전환율입니다. 일반 매출을 즉시 사용 가능한 현금으로 얼마나 잘 전환하는지를 나타냅니다. 비율이 높을수록 현금 창출 능력이 우수합니다. | -36.4% | +7.7% | +53.3% |
| 부채/자본재무 리스크 지표입니다. 차입금으로 구축된 자산과 주주의 자기자본 비율을 비교합니다. 높으면 레버리지가 크고 위험이 큽니다. | 104.2% | +58.3% | +16.6% |
| 유동비율12개월 생존 점검입니다. 현재 보유한 현금과 즉시 현금화 가능한 자산으로 1년 내 갚아야 할 즉시 청구서를 갚을 수 있는지를 비교합니다. 1 이상이면 당장 지급에 충분합니다. | 5.07x | -9.1% | -12.0% |
| 총자산회사의 절대적인 규모입니다. 계산대의 현금, 창고의 재고, 소프트웨어 특허, 공장 등 회사가 보유한 모든 가치 있는 자산을 합친 것입니다. | $129.3M | -20.6% | -4.4% |
| 지표 | 연간 (실적 vs 추정치) | 연간 서프라이즈 | 분기 (실적 vs 추정치) | 분기 서프라이즈 |
|---|---|---|---|---|
| EPS 서프라이즈 | -1.33 vs -1.46 | +9.1% | -0.23 vs -0.26 | +10.4% |
| 매출 서프라이즈 | $90.5M vs $89.6M | +1.0% | $22.8M vs $21.9M | +3.8% |
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | French Glendon E. III | director, officer: President and CEO | Common Stock | D | 4,098 | $2.26 |
| Sep 1, 2026 | French Glendon E. III | director, officer: President and CEO | Common Stock | D | 37,784 | $2.26 |
| Sep 1, 2026 | Radhakrishnan Srikanth | officer: Chief Science & Techn. Officer | Common Stock | D | 2,643 | $2.26 |
| Sep 1, 2026 | Radhakrishnan Srikanth | officer: Chief Science & Techn. Officer | Common Stock | D | 2,121 | $2.26 |
| Sep 1, 2026 | Radhakrishnan Srikanth | officer: Chief Science & Techn. Officer | Common Stock | D | 3,618 | $2.26 |
Operator: Ladies and gentlemen, thank you for standing by. Welcome to Pulmonx' Second Quarter 2026 Earnings Conference Call. Please be advised that today's conference is being recorded. I would like now to turn the call over to Webb Campbell, Investor Relations. Please go ahead. Webb Campbell: Good afternoon, and thank you for joining today's call. Joining me from Pulmonx are Glen French, President and Chief Executive Officer; and Derrick Sung, Chief Operating Officer and Chief Financial Officer. Earlier today, Pulmonx issued a press release announcing its financial results for the quarter-ended June 30, 2026. A copy of the press release is available on the Pulmonx website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements. All forward-looking statements, including, without limitations, those related to our operating trends, commercial strategies and future financial performance including long-term outlook and full year 2026 guidance, the timing and results of clinical trials, physician engagement, expense management, market opportunity, guidance for revenue, gross margin, operating expense, cash usage, commercial expansion and product demand, adoption and pipeline development are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q filed with the SEC on May 4, 2026. Also, during this call, we will discuss certain non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are provided in the press release, which is posted on our Investor Relations website. These non-GAAP measures are not intended to be a substitute for our GAAP results. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, July 29, 2026. Pulmonx disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise. And with that I will turn the call over to Glen. Glendon French: Thank you, Webb. Good afternoon, everyone, and …
| 이름 | 직함 | 보수 | 성별 | 출생 연도 | 상태 |
|---|---|---|---|---|---|
Geoffrey Beran Rose | Chief Commercial Officer | USD 632,293 | Male | 1974 | Active |
David A. Lehman | General Counsel & Secretary | USD 516,643 | Male | 1961 | Active |
Glendon E. French | Chief Executive Officer, President & Director | USD 319,520 | Male | 1962 | Active |
Derrick Sung | Chief Financial Officer & Chief Operating Officer | USD 283,391 | — | 1973 | Active |
Marcee Maroney | Vice President of Marketing | — | Female | 1970 | Active |
Srikanth Radhakrishnan | Chief Science & Technology Officer | — | Male | 1973 | Active |
Narinder S. Shargill | Senior Vice President of Global Medical & Clinical Affairs | — | — | 1955 | Active |
Jérôme Erath | Senior Vice President & GM of International | — | Male | — | Active |
John McKune | VP of Finance & Corporate Controller | — | Male | 1976 | Active |
Lisa Paul | Chief People Officer | — | Female | 1964 | Active |
Pulmonx (LUNG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Pulmonx Corporation (LUNG) Q2 2026 Earnings Call Transcript
Pulmonx NASDAQ: LUNG reported second-quarter revenue of $22.8 million and reiterated its full-year 2026 revenue outlook, while executives highlighted progress in rebuilding the U.S. sales organization, reducing operating expenses and preparing to resume shipments to China.
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.38 per share a year ago.
REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2026 ended June 30, 2026.
